Investors Purchase High Volume of Call Options on Sangamo Therapeutics (NASDAQ:SGMO)

Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) saw some unusual options trading activity on Tuesday. Stock investors bought 6,620 call options on the stock. This represents an increase of approximately 173% compared to the typical daily volume of 2,429 call options.

Sangamo Therapeutics Stock Performance

NASDAQ:SGMO traded up $0.30 on Tuesday, hitting $1.21. 65,541,019 shares of the stock were exchanged, compared to its average volume of 6,337,115. The stock has a market capitalization of $251.95 million, a price-to-earnings ratio of -0.88 and a beta of 1.23. Sangamo Therapeutics has a 52 week low of $0.29 and a 52 week high of $1.48. The company's 50-day moving average price is $0.86 and its 200 day moving average price is $0.66.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last announced its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.01). The firm had revenue of $0.36 million for the quarter, compared to the consensus estimate of $11.40 million. Sangamo Therapeutics had a negative return on equity of 273.25% and a negative net margin of 2,033.69%. As a group, equities research analysts predict that Sangamo Therapeutics will post -0.47 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on SGMO. HC Wainwright reaffirmed a "buy" rating and issued a $5.00 price target on shares of Sangamo Therapeutics in a report on Tuesday. StockNews.com began coverage on Sangamo Therapeutics in a report on Sunday, July 28th. They issued a "sell" rating for the company. One investment analyst has rated the stock with a sell rating, three have given a hold rating and one has assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $2.67.

Institutional Trading of Sangamo Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Wasatch Advisors LP increased its stake in shares of Sangamo Therapeutics by 62.4% in the 1st quarter. Wasatch Advisors LP now owns 20,132,324 shares of the biopharmaceutical company's stock valued at $13,493,000 after acquiring an additional 7,734,400 shares during the last quarter. Acadian Asset Management LLC increased its stake in shares of Sangamo Therapeutics by 4.0% in the 1st quarter. Acadian Asset Management LLC now owns 4,943,260 shares of the biopharmaceutical company's stock valued at $3,311,000 after acquiring an additional 192,385 shares during the last quarter. Renaissance Technologies LLC increased its stake in shares of Sangamo Therapeutics by 58.8% in the 2nd quarter. Renaissance Technologies LLC now owns 4,126,577 shares of the biopharmaceutical company's stock valued at $1,479,000 after acquiring an additional 1,528,600 shares during the last quarter. Marshall Wace LLP increased its stake in shares of Sangamo Therapeutics by 56.3% in the 2nd quarter. Marshall Wace LLP now owns 576,219 shares of the biopharmaceutical company's stock valued at $207,000 after acquiring an additional 207,476 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Sangamo Therapeutics in the 1st quarter valued at about $331,000. 56.93% of the stock is owned by institutional investors.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.